<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04550637</url>
  </required_header>
  <id_info>
    <org_study_id>YL-2020-18</org_study_id>
    <nct_id>NCT04550637</nct_id>
  </id_info>
  <brief_title>A Multi-center Study of Apixaban(APPROACH)</brief_title>
  <official_title>A Multi-center Observative Study of Apixaban After Left Atrial Appendage Occlusion in Patients With Non-valvular Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to enroll approximately 200 cases from 10 research centers&#xD;
      nationwide, completed left atrial appendage occlusion (LAAO) successfully, and give apixaban&#xD;
      (5 mg bid) postoperatively.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Weeks</target_duration>
  <primary_outcome>
    <measure>Incidence of adverse cardiovascular events</measure>
    <time_frame>within 24 weeks after surgery</time_frame>
    <description>all cause death, stroke, transient ischemic attack, systemic embolism</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic/ischemic stroke events</measure>
    <time_frame>within 24 weeks after surgery</time_frame>
    <description>Stroke was defined as patients who developed dysarthria, aphasia, or weakness or sensory loss in the contralateral face, arm, or leg and cerebral ischemia and/or infarction. Diagnosis by clinical symptoms and cranial imaging examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding event</measure>
    <time_frame>within 24 weeks after surgery</time_frame>
    <description>Including dermal, mucosal, nasal, oral, gastrointestinal bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of deaths</measure>
    <time_frame>witnin 24 weeks after surgery</time_frame>
    <description>All cause deaths (cardiac death, and non cardiac death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device related thrombosis</measure>
    <time_frame>12 weeks and 24 weeks after surgery</time_frame>
    <description>Doctors find thrombosis after LAAC by transesophageal echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of cardiovascular disease-related rehospitalization</measure>
    <time_frame>12 weeks and 24 weeks after surgery</time_frame>
    <description>Cardiovascular disease include pericardial effusion, pericardial tamponade, poor cardiac function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>severe adverse events</measure>
    <time_frame>12 weeks and 24 weeks after surgery</time_frame>
    <description>Severe adverse events include re-inpatient for poor cardiac function and other severe adverse events.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Evaluate the Safety and Efficacy of Apixaban</condition>
  <arm_group>
    <arm_group_label>Anticoagulant therapy after percutaneous left atrial appendage</arm_group_label>
    <description>Oral apixaban</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral apixaban</intervention_name>
    <description>apixaban (5 mg bid) is given until 12 weeks after surgery</description>
    <arm_group_label>Anticoagulant therapy after percutaneous left atrial appendage</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study is going to enroll approximately 200 cases who completed left atrial appendage&#xD;
        occlusion (LAAO) successfully from 10 research centers nationwide.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age between 18 to 85 years;&#xD;
&#xD;
          -  understand the purpose of the trial, sign the informed consent form voluntarily&#xD;
&#xD;
          -  successful surgery (no pericardial effusion, pericardial tamponade, or device&#xD;
             displacement during operation; no pericardial effusion before discharge), meet COST&#xD;
             standard during operation.&#xD;
&#xD;
          -  In accordance with the indications for left atrial appendage occlusion: CHA2DS2-VAS2&#xD;
             score≥2 points and/or HAS-BLED score≥3 points&#xD;
&#xD;
          -  unable or unwilling to take oral anticoagulants&#xD;
&#xD;
          -  life expectancy≥1 year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of previous cardiac surgery (valve disease, cardiomyopathy, severe coronary&#xD;
             occlusion);&#xD;
&#xD;
          -  Inability to tolerate trans-esophageal echocardiography;&#xD;
&#xD;
          -  Preoperative trans-esophageal echocardiography suggests thrombus in left atrial&#xD;
             appendage/left atrial;&#xD;
&#xD;
          -  Patients with severe renal insufficiency (creatinine clearance rate&lt;15ml/min);&#xD;
&#xD;
          -  Patients with liver disease accompanied by abnormal blood coagulation and clinically&#xD;
             related bleeding risks;&#xD;
&#xD;
          -  Clinically significant active bleeding;&#xD;
&#xD;
          -  The baseline platelet count is severely reduced: PLT≤50*10^9/L;&#xD;
&#xD;
          -  Severe cardiac insufficiency (preoperative transthoracic echocardiography indicated&#xD;
             LVEF &lt;35%; uncontrolled heart failure (NYHA IV))&#xD;
&#xD;
          -  Allergy or contraindication to anticoagulant drugs such as aspirin, clopidogrel,&#xD;
             apixaban, etc .;&#xD;
&#xD;
          -  Serious heart valve disease or other structural abnormalities need do elective&#xD;
             surgical treatment; or severe coronary heart disease require limited-term&#xD;
             intervention;&#xD;
&#xD;
          -  Less than 45kg or more than 100kg.&#xD;
&#xD;
          -  Take strong CYP3A4 and P-gp inhibitors (including pyrrole antifungal drugs, HIV&#xD;
             protease inhibitors, etc.) for systemic treatment;&#xD;
&#xD;
          -  Patients with other diseases besides atrial fibrillation (such as after mechanical&#xD;
             valve replacement, spontaneous or recurrent venous thromboembolism, etc.) need&#xD;
             anticoagulation treatment;&#xD;
&#xD;
          -  Unsuccessful surgery (serious pericardial tamponade, massive bleeding and other&#xD;
             life-threatening complications occur within 3 days after left atrial appendage&#xD;
             closure);&#xD;
&#xD;
          -  Pregnancy or lactation;&#xD;
&#xD;
          -  Participating in other uncompleted clinical trials;&#xD;
&#xD;
          -  Investigator considers inappropriate subjects.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junbo Ge</last_name>
    <role>Study Chair</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaochun Zhang</last_name>
    <phone>15002121366</phone>
    <email>zhang.xiaochun1@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaochun Zhang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 17, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

